2020
Proceedings of the ASTRO-RSNA Oligometastatic Disease Research Workshop
Yu JB, Brock KK, Campbell AM, Chen A, Diaz R, Escorcia F, Gupta G, Hrinivich WT, Joseph S, Korpics M, Onderdonk BE, Pandit-Taskar N, Wood B, Woodward WA. Proceedings of the ASTRO-RSNA Oligometastatic Disease Research Workshop. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: 539-545. PMID: 32434040, DOI: 10.1016/j.ijrobp.2020.05.018.Peer-Reviewed Original ResearchUltrahypofractionated versus hypofractionated and conventionally fractionated radiation therapy for localized prostate cancer: A systematic review and meta-analysis of phase III randomized trials
Lehrer E, Kishan A, Yu J, Trifiletti D, Showalter T, Ellis R, Zaorsky N. Ultrahypofractionated versus hypofractionated and conventionally fractionated radiation therapy for localized prostate cancer: A systematic review and meta-analysis of phase III randomized trials. Radiotherapy And Oncology 2020, 148: 235-242. PMID: 32505965, DOI: 10.1016/j.radonc.2020.04.037.Peer-Reviewed Original ResearchMeSH KeywordsClinical Trials, Phase III as TopicDose Fractionation, RadiationHumansMaleProspective StudiesProstatic NeoplasmsRadiation Dose HypofractionationRandomized Controlled Trials as TopicConceptsConventionally fractionated radiation therapyHypofractionated radiation therapyUltrahypofractionated radiation therapyLate grade 2Radiation therapyGrade 2Weighted random effects meta-analysesSummary effect sizesLocalized prostate cancerCompare treatment modalitiesDerSimonian and Laird methodPhase III protocolsRandom-effects meta-analysesGenitourinary toxicityEffects meta-analysesGastrointestinal toxicityProspective trialsMedian ageProstate cancerTreatment modalitiesComparing patientsIII protocolLaird methodTherapyMeta-analysis
2016
Weighing Risk of Cardiovascular Mortality Against Potential Benefit of Hormonal Therapy in Intermediate-Risk Prostate Cancer
Lester-Coll N, Johnson S, Magnuson W, Goldhaber S, Sher D, D'Amico A, Yu J. Weighing Risk of Cardiovascular Mortality Against Potential Benefit of Hormonal Therapy in Intermediate-Risk Prostate Cancer. Journal Of The National Cancer Institute 2016, 109: djw281. PMID: 28040795, DOI: 10.1093/jnci/djw281.Peer-Reviewed Original ResearchConceptsIntermediate-risk prostate cancerQuality-adjusted life yearsHormone therapyHistory of myocardial infarctionCardiac risk factorsBiochemical failureProstate cancerRadiation therapyCardiac riskProbability of biochemical failureMonths of hormone therapyRisk factorsMyocardial infarctionYears of follow-upBenefits of HTRisk of cardiovascular mortalityDisease recurrence riskCardiac risk groupsComparing quality-adjusted life-yearsYoung menRecurrence riskFollow-upRisk groupsCardiovascular mortalityLow risk
2015
Trends in Adjuvant and Neoadjuvant Radiotherapy for Cancer Treatment From 1973 to 2011
Le Bui D, Yu J. Trends in Adjuvant and Neoadjuvant Radiotherapy for Cancer Treatment From 1973 to 2011. The Cancer Journal 2015, 21: 147-149. PMID: 26049692, DOI: 10.1097/ppo.0000000000000114.Peer-Reviewed Original ResearchConceptsNeoadjuvant radiation therapyRadiation therapyThyroid cancerCervical cancerKidney cancerRadiation therapy useEnd Results databaseCancer-directed surgeryPercentage of patientsCoordinated careNeoadjuvant radiotherapyOral cavity/pharynxOvarian cancerProstate cancerResults databaseUterine cancerGenitourinary cancersOral cavityPancreatic cancerBladder cancerTherapy useMultidisciplinary clinical teamBreast cancerDisease sitesTherapy usage
2010
Adjuvant radiotherapy after radical prostatectomy: Evidence and analysis
Raldow A, Hamstra D, Kim S, Yu J. Adjuvant radiotherapy after radical prostatectomy: Evidence and analysis. Cancer Treatment Reviews 2010, 37: 89-96. PMID: 20667660, DOI: 10.1016/j.ctrv.2010.07.001.Peer-Reviewed Original ResearchMeSH KeywordsCost-Benefit AnalysisHumansMaleProstatectomyProstatic NeoplasmsRadiotherapy DosageRadiotherapy, AdjuvantRandomized Controlled Trials as TopicSalvage TherapyConceptsTarget volumeIncreased risk of cancer recurrencePositive surgical marginsSeminal vesicle invasionTreatment target volumeLocalized prostate cancerRisk of cancer recurrenceSigns of recurrenceTreatment of patientsTechnical aspects of treatmentDecrease side effectsRandomized clinical trialsUndetectable PSAAdjuvant radiotherapyAdjuvant settingDose escalationExtracapsular extensionRadical prostatectomySurgical marginsRadiation therapyProstate cancerPathological examinationClinical outcomesCure rateCancer recurrence